Global Initiative for Chronic Obstructive Lung Disease 2023
Report: GOLD Executive Summary

Alvar Agustí1,2,2, Bartolome R. Celli2,2,2, Gerard J. Criner3, David Halpin4, Antonio Anzueto5, Peter Barnes6, Jean Bourbeau7, MeiLan K. Han8, Fernando J. Martinez9, Maria Montes de Oca10, Kevin Mortimer6,11,12, Alberto Papi13, Ian Pavord14, Nicolas Roche15, Sundeep Salvi16, Don D. Sin17, Dave Singh18, Robert Stockley19, M. Victorina López Varela20, Jadwiga A. Wedzicha6 and Claus F. Vogelmeier21

1Univ. Barcelona, Hospital Clinic, IDIBAPS and CIBERES, Barcelona, Spain. 2Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA. 3Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA. 4University of Exeter Medical School College of Medicine and Health University of Exeter, Exeter, UK. 5South Texas Veterans Health Care System, University of Texas, San Antonio, TX, USA. 6National Heart and Lung Institute, Imperial College London, London, UK. 7McGill University Health Centre, McGill University, Montreal, QC, Canada. 8University of Michigan, Ann Arbor, MI, USA. 9Weill Cornell Medical Center/New York-Presbyterian Hospital, New York, NY, USA. 10Hospital Universitario de Caracas Universidad Central de Venezuela Centro Médico de Caracas, Caracas, Venezuela. 11Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK. 12School of Clinical Medicine, College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa. 13University of Ferrara, Ferrara, Italy. 14Respiratory Medicine Unit and Oxford Respiratory NIHR Biomedical Research Centre, Nuffield Department of Medicine, University of Oxford, Oxford, UK. 15Pneumologie, Hôpital Cochin AP-HP Centre, Université Paris, Paris, France. 16Pulmocare Research and Education (PURE) Foundation, Pune, India. 17St. Paul’s Hospital, University of British Columbia, Vancouver, BC, Canada. 18University of Manchester, Manchester, UK. 19University Hospital, Birmingham, UK. 20Universidad de la República, Hospital Maciel Montevideo, Montevideo, Uruguay. 21Department of Medicine, Pulmonary and Critical Care Medicine, University Medical Center Giessen and Marburg, Philippus-University, German Center for Lung Research (DZL), Marburg, Germany. 22Co-first authors.

Corresponding author: Alvar Agustí (aagusti@clinic.cat)

Introduction
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) has published the complete 2023 GOLD report, which can be freely downloaded from its webpage (www.goldcopd.org) together with a “pocket guide” and “teaching slide set” [1]. It contains important changes compared to earlier versions, and incorporates 387 new references [1]. Here, we present an executive summary of this GOLD 2023 report [1] that summarizes aspects that 1) are relevant from a clinician’s perspective and 2) updates evidence published since the prior executive summary in 2017.

New definition of COPD
The definition of a disease should only include the characteristics that distinguish it from other diseases [2]. Accordingly, GOLD 2023 proposes a new definition of COPD that, at variance with previous documents [3], focuses exclusively on these characteristics, separately from its epidemiology, causes, risk factors and diagnostic criteria that are discussed on their own.

GOLD 2023 defines COPD as a heterogeneous lung condition characterized by chronic respiratory symptoms (dyspnea, cough, expectoration and/or exacerbations) due to abnormalities of the airways (bronchitis, bronchiolitis) and/or alveoli (emphysema) that cause persistent, often progressive, airflow obstruction.
Pathogenesis: causes and risk factors
COPD results from dynamic, cumulative and repeated gene (G)–environment (E) interactions over the lifetime (T) that damage the lungs and/or alter their normal development/aging processes (GETomics) [4].

Environmental risk factors
Cigarette smoking is a key environmental risk factor for COPD. Cigarette smokers have a higher prevalence of respiratory symptoms and lung function abnormalities, a greater annual rate of forced expiratory volume in 1 s (FEV1) decline and a greater COPD mortality rate than nonsmokers [5], yet fewer than 50% of heavy smokers develop COPD [6]. Passive exposure to cigarette smoke, other types of tobacco smoke (e.g. pipe, cigar, water pipe) [7–9], and marijuana [10] are also risk factors for COPD [11]. Smoking during pregnancy poses a risk for the fetus, by altering lung growth and development in utero, and possibly priming the immune system for abnormal/enhanced responses in the future [4, 12]. In low- and middle-income countries (LMICs), COPD in nonsmokers may be responsible for up to 60–70% of cases [13]. Because the LMICs contribute to over 85% of all COPD cases, nonsmoking risk factors account for over 50% of the global burden of COPD [13]. Wood, animal dung, crop residues, and coal (i.e. biomass), typically burned in poorly functioning stoves, may lead to very high levels of household air pollution [14], which is associated with increased COPD risk, although the extent to which household air pollution versus other poverty-related exposures explain the association is unclear [15, 16]. Compared to COPD in smokers, COPD in nonsmokers is more common in females, of younger age, who exhibit similar (or milder) respiratory symptoms and quality of life impairment. They have similar spirometric indices but greater small airways obstruction, less emphysema and lesser rate of lung function decline. Finally they show lower neutrophil count, higher eosinophil numbers in the sputum [13] and a similar defect in macrophage phagocytosis of pathogenic bacteria [17]. Research is needed to understand how interventions aimed at decreasing household air pollution can reduce the risk of COPD as well as what is the most appropriate pharmacotherapy for this type of COPD [13].

Occupational exposures, including organic and inorganic dusts, chemical agents, and fumes, are an under-appreciated environmental risk factor for COPD [18, 19]. The US National Health and Nutrition Examination Survey III estimated the fraction of COPD attributable to workplace exposures was 19.2% overall, and 31.1% among never-smokers [20].

Air pollution, which typically consists of particulate matter (PM), ozone, oxides of nitrogen or sulfur, heavy metals, and other greenhouse gases, is a major worldwide cause of COPD, responsible for ~50% of the attributable risk for COPD in LMICs [1]. The risk of air pollution to individuals is dose-dependent with no apparent “safe” threshold. Even in countries with relatively low ambient air pollution levels, chronic exposure to PM <2.5 μm and nitrogen dioxides significantly impairs lung growth in children [21], accelerates lung function decline in adults and increases the risk for COPD, especially among those with additional risk factors [22]. Air pollution also increases the risk of COPD exacerbations, hospitalizations, and mortality [23].

Genetic risk factors
The most relevant genetic risk factor for COPD identified are mutations in SERPINA1, leading to alpha-1 antitrypsin deficiency, a major circulating inhibitor of serine proteases [24]. The PiZZ genotype affects 0.12% of COPD patients, and its prevalence ranges from 1/408 in Northern Europe to 1/1274 in Eastern Europe [25]. There is no increased COPD risk in heterozygotes (MZ and SZ) in the absence of smoking [26].

Other genetic variants have also been associated with reduced lung function and risk of COPD, their individual effect size is small although their co-occurrence may increase disease susceptibility [27].

Lung function trajectories: lung development and aging
At birth, the lungs are not fully developed. They grow and mature until about 20–25 years of age (earlier in females), when lung function reaches its peak [5]. This is followed by a relatively short plateau and a final phase of mild lung function decline due to physiological lung aging. This normal lung function trajectory can be altered by processes occurring during gestation, birth, childhood, and adolescence that affect lung growth (hence, peak lung function) and/or processes shortening the plateau phase and/or accelerating the aging phase [28]. Indeed, in the general population there is a range of lung function trajectories through the lifetime [28]. Trajectories below the normal range are associated with a higher prevalence and earlier incidence of multimorbidity and premature death [29], whereas those above the
normal range are associated with healthier aging, fewer cardiovascular and respiratory events, as well as with a survival benefit [30, 31].

Factors in early life termed “childhood disadvantage factors”, including prematurity, low birth weight, maternal smoking during pregnancy, repeated respiratory infections and poor nutrition, among others, are key determinants of peak lung function attained in early adulthood [32–39]. Reduced peak lung function in early adulthood increases the risk of COPD later in life [32, 40, 41]. In fact, approximately 50% of patients develop COPD due to accelerated decline in $FEV_1$ over time while the other 50% develop it due to abnormal lung growth and development (with normal lung function decline over time) [42].

**Sex**

The prevalence of COPD in developed countries is now almost equal in males and females [43]. Women report more dyspnea, worse health status scores and have a higher incidence of exacerbations compared with men at similar severity of airflow limitation [44].

**Socioeconomic status**

Poverty and lower socioeconomic status are consistently associated with airflow obstruction [45] and increased risk of COPD [46]. It is likely that this reflects exposures to household and outdoor air pollutants, crowding, poor nutrition, infections, or other factors related to low socioeconomic status.

**Asthma**

Many different studies have reported that asthma and atopy in infancy may be a significant risk factor for COPD in adulthood [47, 48]. However, it is important to remember that abnormal lung development in childhood and adolescence can cause asthma-like symptoms. Given that poor lung development is associated with COPD in adulthood (see above), some of these infants and adolescents may have been mislabeled as “asthma”.

**Infections**

Severe respiratory infections in childhood have been associated with reduced lung function and increased respiratory symptoms in adulthood [47, 49]. In adults, chronic bronchial infection, particularly with *Pseudomonas aeruginosa*, is associated with accelerated $FEV_1$ decline [50]. In many parts of the world, tuberculosis [51] and HIV infection [52] are also important risk factors for COPD.

**Diagnosis: forced spirometry**

A diagnosis of COPD should be considered in any patient who complains of dyspnea, chronic cough or sputum production, a history of recurrent lower respiratory tract infections and/or a history of exposure to risk factors for the disease (see above) but forced vital capacity (FVC) maneuver during spirometry showing the presence of a post-bronchodilator $FEV_1/FVC <0.7$ is needed to establish the diagnosis of COPD. The $FEV_1$ also serves to determine the severity of airflow obstruction (GOLD grades 1, 2, 3, and 4, or mild, moderate, severe, and very severe). Yet, several important aspects related to forced spirometry need to be considered here.

First, airflow obstruction that is not fully reversible is not specific for COPD. For instance, it may also be found in patients with asthma and other diseases, so the clinical context and risk factors (see above) must also be considered when establishing a diagnosis of COPD.

Second, if the post-bronchodilator $FEV_1/FVC$ ratio is between 0.60 and 0.80 on a single spirometric measurement, this should be confirmed by repeat spirometry on a separate occasion, as in some cases the ratio may change as a result of biological variation when measured at a later interval [53, 54]. When the initial post-bronchodilator $FEV_1/FVC$ ratio is <0.6, it is very unlikely to rise spontaneously above 0.7 [53].

Third, there is a long-standing debate on whether it is better to use a fixed $FEV_1/FVC$ ratio <0.7 or the lower limit of normal (LLN) for the diagnosis of COPD. GOLD favors the use of the former because it is simple and independent of reference values, since it relates to variables measured in the same individual and has been used in all the clinical trials that form the evidence base on which treatment recommendations are drawn. GOLD 2023 acknowledges that use of a fixed $FEV_1/FVC$ ratio <0.7 to define airflow obstruction may under-diagnose young adults and over-diagnose the elderly [55, 56], especially in mild disease, compared to using the LLN values of $FEV_1/FVC$. LLN values are based on the normal distribution and classify the bottom 5% of the healthy population as abnormal. Thus, LLN values are highly dependent on the choice of reference equations as well as race/ethnicity, and there are no longitudinal studies available validating the use of the LLN. Further, using the fixed ratio is not inferior to...
EUROPEAN RESPIRATORY JOURNAL GOLD EXECUTIVE SUMMARY | A. AGUSTÍ ET AL.

50 years, GOLD proposes to operationally consider of the patient [62]. Given that lung function peaks at around 20 years [5] and starts to decline around 40 plateau and/or early lung function decline [64, 65]. COPD in whether from having never achieved normal peak lung function in early adulthood and/or from shorter longevity noted. Thus, GOLD proposes to use the term "Young COPD" only to discuss the "biological" first steps of the disease in an experimental setting.

**Mild COPD**

Some studies have used “mild" airflow obstruction as a surrogate for “early” disease [61]. This assumption is incorrect because not all patients started their journey from a normal peak lung function in early adulthood, so some of them may never suffer “mild” disease in terms of “severity” of airflow obstruction [28]. Further, “mild” disease can occur at any age and may progress, or not, over time [60]. Accordingly, GOLD proposes that “mild" should be used only to describe the severity of airflow obstruction measured spirometrically.

**Young COPD**

The term “young COPD” is seemingly straightforward because it directly relates to the “chronological” age of the patient [62]. Given that lung function peaks at around 20 years [5] and starts to decline around 40–50 years, GOLD proposes to operationally consider “young COPD” in patients aged 20–50 years [63], whether from having never achieved normal peak lung function in early adulthood and/or from shorter longevity and/or early lung function decline [64, 65]. COPD in “young” people may be associated with significant structural and functional lung abnormalities with substantial impact on health [65, 66]. A family history of respiratory diseases and/or early-life events (including hospitalizations before the age of 5 years) is reported by a significant proportion of young patients with COPD [65].

**Pre-COPD**

This term has been proposed to identify individuals of any age, with respiratory symptoms and/or other detectable structural (e.g. emphysema) and/or functional abnormalities (e.g. hyperinflation, reduced lung diffusing capacity, or rapid FEV₁ decline), in the absence of airflow obstruction on post-bronchodilator spirometry (i.e., FEV₁/FVC >0.7) [67]. These patients may (or not) develop persistent airflow obstruction (i.e. COPD) over time [67]. Yet, people with pre-COPD so defined should already be considered “patients” because they suffer symptoms and/or have functional and/or structural abnormalities. Currently, there is no evidence on what the best treatment is for these patients [68]. There urgently is a need for randomized controlled trials of interventions in this population.
controlled trials, both in patients with “Pre-COPD”, and in young people with COPD [69]. Research in this area would benefit from pediatric-to-adulthood cohorts and more active case-finding strategies.

**PRISm**

This term has been proposed to describe individuals with FEV₁/FVC ≥0.7 and FEV₁ <80% of reference after bronchodilation [70, 71]. Its prevalence ranges from 7.1% to 20.3% [71], is particularly high in current and former smokers, and is associated with increased all-cause mortality [71]. PRISm can transition to normal, obstructive or restrictive spirometry over time [71]. Despite an increasing body of literature on PRISm, significant knowledge gaps remain in relation to its pathogenesis and treatment [71].

**Taxonomy**

Based on the different causes (or etiotypes) that can contribute to COPD (see above) GOLD 2023 proposes a new taxonomic classification of COPD (figure 1) that reflects two recent proposals [2, 72]. It aims to raise awareness about nonsmoking-related COPD and to stimulate research on the mechanisms and corresponding diagnostic, preventive or therapeutic approaches for these other etiotypes of COPD which are highly prevalent around the globe [13].

**Clinical presentation**

Patients with COPD may complain of dyspnea, wheezing, chest tightness, fatigue, activity limitation and/or cough with or without sputum production and may experience acute respiratory events characterized by acute worsening of respiratory symptoms called exacerbations that require specific preventive and therapeutic measures. Patients with COPD frequently harbor other comorbid diseases (multimorbidity) that influence their clinical condition and prognosis [73], independently of the severity of airflow obstruction due to COPD [73], and require specific treatment (see below).

**Assessment**

Once the diagnosis of COPD has been confirmed by spirometry, the goals of the initial assessment of COPD to guide therapy are to determine: 1) the severity of airflow limitation (GOLD spirometric grades); 2) the nature and magnitude of current symptoms; 3) the previous history of moderate and severe

---

**Proposed taxonomy (etiotypes) for COPD**

<table>
<thead>
<tr>
<th>Classification</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Genetically determined COPD (COPD-G)</td>
<td>Alpha-1 antitrypsin deficiency (AATD) Other genetic variants with smaller effects acting in combination</td>
</tr>
<tr>
<td>COPD due to abnormal lung development (COPD-D)</td>
<td>Early life events, including premature birth and low birthweight, among others</td>
</tr>
<tr>
<td>Environmental COPD</td>
<td>• Exposure to tobacco smoke, including <em>in utero</em> or via passive smoking • Vaping or e-cigarette use • Cannabis</td>
</tr>
<tr>
<td>Cigarette smoking COPD (COPD-C)</td>
<td>Exposure to household pollution, ambient air pollution, wildfire smoke, occupational hazards</td>
</tr>
<tr>
<td>Biomass and pollution exposure COPD (COPD-P)</td>
<td>Childhood infections, tuberculosis-associated COPD, HIV-associated COPD</td>
</tr>
<tr>
<td>COPD due to infections (COPD-I)</td>
<td>Particularly childhood asthma</td>
</tr>
<tr>
<td>COPD and asthma (COPD-A)</td>
<td></td>
</tr>
<tr>
<td>COPD of unknown cause (COPD-U)</td>
<td></td>
</tr>
</tbody>
</table>

Adapted from Celli et al. [2] and Stolz et al. [72].
exacerbations (the best estimate of the risk of future exacerbations); and 4) the presence and type of multimorbidity.

**Combined initial COPD assessment: from ABCD to ABE**

GOLD 2023 modifies the ABCD assessment tool of previous editions [74] to recognize the clinical impact of exacerbations independently of the level of symptoms of the patient [75] (figure 2). The thresholds proposed for symptoms (X axis) and history of exacerbations in the previous year (Y axis) are unchanged from previous GOLD documents, so the A and B groups remain unchanged, while the former C and D groups are now merged into a single group termed “E” (for “Exacerbations”). This has implications for the initial pharmacological treatment recommendations, as discussed below. The practical value of this proposal needs to be validated by appropriate clinical research.

**Imaging**

A chest X-ray cannot confirm a diagnosis of COPD. However, radiological changes associated with COPD may include signs of lung hyperinflation (flattened diaphragm and increased retrosternal air space), lung hyperlucency, and rapid tapering of the vascular markings. On the other hand, a chest X-ray can help exclude alternative diagnoses and establish the presence of significant comorbidities such as concomitant pulmonary fibrosis, bronchiectasis, pleural diseases, kyphoscoliosis, and cardiomegaly.

**Computed tomography (CT) of the chest** can provide information of potential clinical relevance, including: 1) presence, severity, and distribution of emphysema; this has implications for potential surgical or endoscopic lung volume reduction, is associated with faster FEV₁ decline, higher mortality and increased risk of lung cancer [76]; 2) about 30% of COPD patients have bronchiectasis visible on CT, which is associated with increased exacerbation frequency and mortality [77]; 3) most COPD patients fulfil the inclusion/exclusion criteria for lung cancer screening in the general population [78, 79], so they should be offered a similar strategy [1]; 4) quantification of airway abnormalities, although these methods are less well standardized than those used for emphysema quantification [80–82]; and, 5) a CT offers information about COPD comorbidities including coronary artery calcifications, pulmonary artery enlargement, bone

---

**FIGURE 2** GOLD ABE assessment tool. Exacerbation history refers to exacerbations suffered the previous year. mMRC: modified Medical Research Council Dyspnea Questionnaire; CAT: COPD Assessment Test; FEV₁: forced expiratory volume in 1 s; FVC: forced vital capacity. Reproduced with permission from www.goldcopd.org

https://doi.org/10.1183/13993003.00239-2023
density and muscle mass, some of which are associated with all-cause mortality independently of the severity of airflow obstruction [83]. Thus, GOLD 2023 recommends chest CT in COPD patients with persistent exacerbations, symptoms out of proportion to airflow limitation severity, severe airflow obstruction with significant hyperinflation and gas trapping, or for those who meet criteria for lung cancer screening.

Pharmacological treatment
Pharmacological therapy must be always associated with non-pharmacological measures described later, starting with smoking cessation when needed.

Choice and appropriate use of inhaler devices
Because inhaled therapy is the cornerstone of COPD treatment, the appropriate use of these devices is crucial to optimize the benefit–risk ratio of any inhaled therapy. Achieving this goal requires educating and training the providers and the patients in the correct use of the device. Regular assessment at follow-up is necessary to maintain their effective use. Details on the choice of device can be found in the complete GOLD 2023 document and include availability, patient preferences and ability to perform the correct inhalation maneuver [84].

Initial pharmacological treatment
Figure 3 shows the 2023 GOLD recommendation for initiation of pharmacological therapy. The treatment of patients in Group A has not changed. In contrast, for patients in Group B, a dual long-acting bronchodilator combination (β2 adrenergic (LABA) + anti-muscarinic (LAMA) bronchodilators) is now recommended since dual therapy is more effective than monotherapy with similar side-effects [85–87]. For patients in Group E, LAMA+LABA is also the recommended initial therapy, except for those patients with blood eosinophils ≥300 cells·µL−1, in whom starting triple therapy (LABA+LAMA+inhaled corticosteroid (ICS)) can be considered. This is a practical recommendation; direct evidence is not available to guide therapy in naïve individuals. The role of the blood eosinophil count for the reduction of the exacerbation risk with ICS is explicitly discussed below. The use of LABA+ICS in COPD is no longer encouraged. If there is an indication for an ICS, then LABA+LAMA+ICS has been shown to be superior to LABA+ICS and is therefore the preferred choice [88, 89]. If patients with COPD have concomitant asthma, they should be treated as if they have asthma [90].

<table>
<thead>
<tr>
<th>Group E</th>
<th>Group A</th>
<th>Group B</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥2 moderate exacerbations or ≥1 leading to hospitalization</td>
<td>A bronchodilator</td>
<td>LABA+LAMA*</td>
</tr>
<tr>
<td>0 or 1 moderate exacerbations (not leading to hospital admission)</td>
<td>mMRC 0–1, CAT &lt;10</td>
<td>mMRC ≥2, CAT ≥10</td>
</tr>
</tbody>
</table>

* single inhaler therapy may be more convenient and effective than multiple inhalers
Exacerbations refers to the number of exacerbations per year

FIGURE 3 Initial pharmacological treatment. mMRC: modified Medical Research Council Dyspnea Questionnaire; CAT: COPD Assessment Test; LAMA: long-acting anti-muscarinic antagonist; LABA: long-acting β2 receptor agonist; ICS: inhaled corticosteroid; eos: eosinophils. Reproduced with permission from www.goldcopd.org
Follow-up pharmacological treatment

Following initial therapy, patients should be reassessed guided by the principles of first review and assess, then adjust if needed.

GOLD 2023 continues to recommend that follow-up treatment be based on two key treatable traits (TTs) [91]: dyspnea and occurrence of exacerbations (figure 4). TTs can be identified based on clinical recognition (phenotypes) and/or on deep understanding of critical causal pathways (endotypes) through validated biomarkers (e.g. circulating eosinophils to guide treatment with ICS in COPD patients with evidence of T2 inflammation) [91]. Importantly, TTs can co-exist in the same patient [92] and change with time (spontaneously or because of treatment). GOLD 2023 recommendations for follow-up treatment for both TTs (dyspnea and exacerbations) broadly follow previous recommendations but no longer include LABA+ICS for the reasons stated above (see initial treatment).

For patients with persistent dyspnea or exercise limitation on bronchodilator monotherapy, a step up to LABA+LAMA is recommended. If this does not improve symptoms clinicians should consider switching inhaler device or molecules, as well as investigating and treating other causes of dyspnea.

---

**Follow-up pharmacological treatment**

1. **If response to initial treatment is appropriate, maintain it**
   - Check adherence, inhaler technique and possible interfering comorbidities
   - Consider the predominant treatable trait to target (dyspnea or exacerbations)
   - Use exacerbation pathway if both exacerbations and dyspnea need to be targeted
   - Place patient in box corresponding to current treatment and follow indications
   - Assess response, adjust and review
   - These recommendations do not depend on the ABE assessment at diagnosis

2. **If not:**
   - Consider switching inhaler device or molecules
   - Implement or escalate non-pharmacologic treatment(s)
   - Investigate (and treat) other causes of dyspnea

---

**FIGURE 4** Follow-up pharmacological treatment. LAMA: long-acting anti-muscarinic antagonist; LABA: long-acting β2 receptor agonist; ICS: inhaled corticosteroid; eos: eosinophils; FEV1: forced expiratory volume in 1 s. Reproduced with permission from www.goldcopd.org

---

https://doi.org/10.1183/13993003.00239-2023
For patients continuing to have exacerbations (with or without dyspnea) on bronchodilator monotherapy, escalation to LABA+LAMA is recommended, except for patients with blood eosinophils $\geq 300\ \text{cells}\cdot\mu\text{L}^{-1}$ who may be escalated to LABA+LAMA+ICS. For patients with persistent exacerbations on LABA+LAMA, escalation to LABA+LAMA+ICS is recommended if they have blood eosinophils $\geq 100\ \text{cells}\cdot\mu\text{L}^{-1}$. For patients continuing to exacerbate despite therapy with LABA+LAMA+ICS or those who have an eosinophil count of $<100\ \text{cells}\cdot\mu\text{L}^{-1}$, the addition of roflumilast (particularly in patients with chronic bronchitis and an FEV$_1$ <50% predicted) [93–95] or a macrolide (particularly in patients who are not current smokers) may be considered [96, 97].

Patients whose pharmacological treatment is modified should be closely monitored. Treatment escalation has not been systematically tested and trials of de-escalation are limited to withdrawing ICS [98]. As indicated in figure 4, ICS de-escalation can be considered if pneumonia or other considerable side-effects occur. In case of blood eosinophils $\geq 300\ \text{cells}\cdot\mu\text{L}^{-1}$, ICS de-escalation is more likely to be associated with development of exacerbations. Finally, if a patient with COPD and no features of asthma has already been treated – for whatever reason – with LABA+ICS and is well controlled in terms of symptoms and exacerbations, then LABA+ICS could be continued. However, if they remain dyspneic switching to LABA+LAMA should be considered, and if they have further exacerbations, treatment should be escalated to LABA+LAMA+ICS.

Other therapeutic considerations

The eosinophil as a useful clinical biomarker

As in previous GOLD reports, the main factors to consider whether to initiate ICS treatment is based on a patient’s previous exacerbation history, and the blood eosinophil count (figure 5) [88, 89, 99–102]. Adding ICS has little or no effect at a blood eosinophil count $<100\ \text{cells}\cdot\mu\text{L}^{-1}$ whilst blood eosinophils $\geq 300\ \text{cells}\cdot\mu\text{L}^{-1}$ identify patients with a strong likelihood of treatment benefit [103, 104]. There is a continuous gradation of the preventive effect of ICS in patients with eosinophil values between 100 and 300 cells$\cdot\mu\text{L}^{-1}$, so some patients are likely to get benefit from adding ICS [103, 104]. Treatment decisions

Factors to consider when initiating ICS treatment

Factors to consider when adding ICS to long-acting bronchodilators:

(2) despite appropriate long-acting bronchodilator maintenance therapy (see Figure 4 and GOLD report Table 3.4 for recommendations). Note that blood eosinophils should be seen as a continuum; quoted values represent approximate cut-points; eosinophil counts are likely to fluctuate.

Adapted from and reproduced with permission from [103].

FIGURE 5 Factors to consider when adding treatment with inhaled corticosteroids (ICS) to long-acting bronchodilators (note the scenario is different when considering ICS withdrawal). Reproduced with permission from www.goldcopd.org

https://doi.org/10.1183/13993003.00239-2023
can be based on historical eosinophil counts as the repeatability of blood eosinophil counts in a large primary care population appears reasonable [105], although greater variability is observed at higher thresholds [106].

**Chronic bronchitis**
Chronic bronchitis (CB) has been traditionally defined by “cough and sputum production for at least 3 months per year for two consecutive years” (in the absence of another cause that can explain this, a caveat that is often forgotten). The prevalence of CB in COPD patients ranges from 27% to 35%, being higher in males, younger age, greater pack-years of smoking, more severe airflow obstruction, rural location and increased occupational exposures. CB is associated with accelerated lung function decline, exacerbations, and mortality in COPD patients. Treatment of CB is unresolved but can include smoking cessation, long-acting muscarinic antagonists, oral mucolytics and antioxidants or oscillating positive expiratory pressure therapy; the use of inhaled mucolytics or recombinant human DNase have not shown promise [1]. Liquid nitrogen metered cryospray, rheoplasty, and targeted lung denervation are currently undergoing evaluation for CB treatment.

**Affordability of inhaled medicines**
In LMICs, there is limited availability and affordability of essential inhaled therapies for people with COPD, and this global inequity must be addressed urgently as part of efforts to achieve Universal Health Coverage and Sustainable Development Goal 3 [107]. On the other hand, even in developed countries, most inhaled medicines are still branded.

**Reducing lung function decline and mortality in COPD**
Pharmacotherapy has the potential to reduce the rate of lung function decline, but further studies are needed to know what patients can benefit most since not all patients exhibit accelerated lung function decline [1]. On the other hand, a number of pharmacological and non-pharmacological interventions (figure 6) reduce mortality in selected COPD patients. This emphasizes the need to implement targeted case-finding strategies, apply adequate patient characterization and provide appropriately individualized therapy.

**Non-pharmacological therapy**
Non-pharmacological treatment is a key part of the comprehensive management of COPD.

**Education**
All patients should receive basic information about COPD and its treatment (respiratory medications and inhalation devices), strategies to minimize dyspnea, and advice about when to seek help.

**Smoking cessation**
Approximately 40% of people with COPD continue to smoke despite knowing they have the disease, and this behavior has a negative impact on prognosis and progression of the disease [108]. All patients who continue to smoke should be offered help and treatment to quit.

**Vaccination**
Depending on local guidelines, patients should be offered vaccination against influenza, pneumococcus, coronavirus disease 2019 (COVID-19), pertussis, and herpes zoster, if they have not already received these [1].

**Physical activity**
Physical activity is decreased in COPD patients [109] so all COPD patients should be encouraged to keep active. The challenge is promoting and maintaining physical activity [110, 111]. Technology-based interventions have the potential to provide convenient and accessible means to enhance exercise self-efficacy, and to educate and motivate patients to make healthy lifestyle changes [112].

**Pulmonary rehabilitation**
Pulmonary rehabilitation (PR), including community- and home-based, is beneficial [1]. Accordingly, patients with high symptom burden and risk of exacerbations (GOLD groups B and E) should be recommended to take part in a formal PR program designed and delivered in a structured manner, considering the individual’s COPD characteristics and comorbidities [113–116].

Tele-rehabilitation has been proposed as an alternative to the traditional approaches. This has become even more relevant in the COVID-19 pandemic era where in-person PR has not been feasible. However, it is important to distinguish between evidence-based tele-rehabilitation models and pandemic-adapted models. Multiple trials performed in groups and individuals with a large variety of tele-rehabilitation delivery...
Evidence supporting a reduction in mortality with pharmacotherapy and non-pharmacotherapy in COPD patients

<table>
<thead>
<tr>
<th>Therapy</th>
<th>RCT*</th>
<th>Treatment effect on mortality</th>
<th>Patient characteristics</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Pharmacotherapy</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LABA+LAMA+ICS1</td>
<td>Yes</td>
<td>Single inhaler triple therapy compared to dual LABD therapy relative risk reduction: IMPACT: HR 0.72 (95% CI 0.53, 0.99)1a ETHOS: HR 0.51 (95% CI 0.33, 0.80)1b</td>
<td>Symptomatic people with a history of frequent and/or severe exacerbations</td>
</tr>
<tr>
<td><strong>Non-pharmacological therapy</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Smoking cessation2</td>
<td>Yes</td>
<td>HR for usual care group compared to intervention group (smoking cessation) HR 1.18 (95% CI 1.02, 1.37)2</td>
<td>Asymptomatic or mildly symptomatic</td>
</tr>
<tr>
<td>Pulmonary rehabilitation3</td>
<td>Yes</td>
<td>Old trials: RR 0.28 (95% CI 0.10, 0.84)3a New trials: RR 0.68 (95% CI 0.28, 1.67)3b</td>
<td>Hospitalized for exacerbations of COPD (during or ≤4 weeks after discharge)</td>
</tr>
<tr>
<td>Long-term oxygen therapy4</td>
<td>Yes</td>
<td>NOTT: ≥19 hours of continuous oxygen vs ≤13 hours: 50% reduction4a MRC: ≥15 hours vs no oxygen: 50% reduction4b</td>
<td>PaO2 ≤55 mmHg or &lt;60 mmHg with cor pulmonale or secondary polycythemia</td>
</tr>
<tr>
<td>Noninvasive positive pressure ventilation5</td>
<td>Yes</td>
<td>12% in NPPV (high IPAP level) and 33% in control HR 0.24 (95% CI 0.11, 0.49)5</td>
<td>Stable COPD with marked hypercapnia</td>
</tr>
<tr>
<td>Lung volume reduction surgery6</td>
<td>Yes</td>
<td>0.07 deaths per person-year (LVRS) vs 0.15 deaths per person-year (UC) RR for death 0.47 (p=0.005)6</td>
<td>Upper lobe emphysema and low exercise capacity</td>
</tr>
</tbody>
</table>

* RCT with pre-specified analysis of the mortality outcome (primary or secondary outcome); ‡: inconclusive results likely due to differences in pulmonary rehabilitation across a wide range of participants and settings.

1. a) IMPACT trial [192] and b) ETHOS trials [89]; 2. Lung Health Study [193]; 3. a) PUHAN et al. [156] and b) PUHAN et al. [157] and RYRSØ et al. [194]; 4. a) NOTT [195] and b) MRC [196]; 5. KOHLEIN et al. [197]; 6. NETT trial [198].

FIGURE 6 Evidence supporting a reduction in mortality with pharmacotherapy and non-pharmacotherapy in COPD patients. RCT: randomized controlled trial; ICS: inhaled corticosteroids; IPAP: inspiratory positive airway pressure; LABD: long-acting bronchodilator; LABA: long-acting β2 agonist; LAMA: long-acting anti-muscarinic antagonist; PaO2: arterial partial pressure of oxygen; NPPV: noninvasive positive pressure ventilation; LVRS: lung volume reduction surgery; UC: usual treatment control group. Reproduced with permission from www.goldcopd.org

Platforms (videoconferencing, telephone only, website with telephone support, mobile application with feedback, centralized “hub” for people to come together) suggest that tele-rehabilitation is safe and has similar benefits to those of center-based PR across a range of outcomes [117]. However, the optimal form of delivery, content and duration are not yet established [118, 119].

**Oxygen therapy and ventilatory support**
The criteria for prescribing long-term oxygen therapy and ventilator support remain unchanged and are described in detail in the GOLD 2023 report [1].

**Surgical and endoscopic lung volume reduction**
In selected patients with symptomatic heterogeneous or homogenous emphysema and significant hyperinflation refractory to optimized medical care, surgical or bronchoscopic modes of lung volume reduction may be considered (figure 7). In patients with a large bulla, surgical bullectomy is an option,
and in selected patients with very severe COPD and without relevant contraindications, lung transplantation may be considered.

**End of life and palliative care**
All patients with advanced COPD should be considered for end of life and palliative care support to optimize symptom control and allow patients and their families to make informed choices about future management.

**Exacerbations of COPD**

**A new definition**
Exacerbations of COPD (ECOPD) negatively impact health status, disease progression and prognosis [120]. The previous GOLD definition of ECOPD was highly non-specific (“acute worsening of respiratory symptoms that results in additional therapy”) [3].

Besides, the severity of ECOPD was determined post facto (mild, moderate or severe) based on the use of healthcare resources [3], which is useless to guide treatment at the point of care.

To address these limitations, GOLD 2023 has adopted the recent consensus Rome proposal [120] which defines ECOPD as: “an event characterized by dyspnea and/or cough and sputum that worsen over \( \leq 14 \) days, which may be accompanied by tachypnea and/or tachycardia and is often associated with increased local and systemic inflammation caused by airway infection, pollution, or other insult to the airways”.

---

**FIGURE 7** Surgical and interventional therapies in advanced emphysema. Homogeneous emphysema was defined as <10% difference in emphysematous destruction between the targeted and ipsilateral non-targeted lobe undergoing lung reduction as measured by quantitative chest computed tomography (CT) imaging. By contrast, >10% difference between the targeted and non-targeted lobe is considered a heterogeneous pattern of emphysematous destruction. CV: collateral ventilation measure by Chartis; Fi+: fissure integrity >90% by high-resolution CT (HRCT); Fi−: fissure integrity <90% by HRCT; ELVR: endoscopic lung volume reduction; EBV: endobronchial valve; VA: vapor ablation; LVRC: lung volume reduction coil; LVRS: lung volume reduction surgery. Reproduced with permission from www.goldcopd.org
Differential diagnosis

Patients with COPD are at increased risk of other acute events, particularly decompensated heart failure, pneumonia and/or pulmonary embolism that may mimic or aggravate an ECOPD (figure 8) [121]. Thus, while worsening of dyspnea, particularly if associated with cough and, purulent sputum, and no other symptoms or signs in a patient with COPD may be diagnosed as an ECOPD, other patients may have worsening of respiratory symptoms, particularly dyspnea without the classic characteristics of ECOPD, that should prompt careful consideration and/or search of those potential confounders, or contributors [121].

Classification of the severity of COPD exacerbations

<table>
<thead>
<tr>
<th>Severity</th>
<th>Variable thresholds to determine severity</th>
</tr>
</thead>
</table>
| Mild (default)   | - Dyspnea VAS <5  
- RR < 24 breaths·min⁻¹  
- HR < 95 bpm  
- Resting SaO₂ ≥92% breathing ambient air (or patient’s usual oxygen prescription) AND change ≤3% (when known)  
- CRP < 10 mg·L⁻¹ (if obtained)                                                                 |
| Moderate (meets at least three of five*) | - Dyspnea VAS ≥5  
- RR ≥ 24 breaths·min⁻¹  
- HR ≥ 95 bpm  
- Resting SaO₂ <92% breathing ambient air (or patient’s usual oxygen prescription) AND/OR change >3% (when known)  
- CRP ≥ 10 mg·L⁻¹  
*: if obtained, ABG may show hypoxemia (PaO₂ ≤60 mmHg) and/or hypercapnia (PaCO₂ >45 mmHg) but no acidosis |
| Severe           | - Dyspnea, RR, HR, SaO₂ and CRP same as moderate  
- ABG show new onset/worsening hypercapnia and acidosis (PaCO₂ >45 mmHg and pH <7.35)                                                                 |

Determine etiology: viral testing, sputum culture, other

Adapted from: The ROME Proposal, Celli et al. [120]

FIGURE 8 Classification of the severity of COPD exacerbations (ECOPD). VAS: visual analog scale; RR: respiratory rate; HR: heart rate; CRP: C-reactive protein. SaO₂: arterial oxygen saturation; PaO₂: arterial partial pressure of oxygen; PaCO₂: arterial partial pressure of carbon dioxide; ABG: arterial blood gases. ABG should show new onset/worsening hypercapnia or acidosis since a few patients may have chronic hypercapnia. Reproduced with permission from www.goldcopd.org
Assessment of ECOPD severity

Based on a thorough review of the available literature and using a Delphi approach to agree on the variable thresholds, the Rome proposal suggests using easy to obtain clinical variables to define the severity of ECOPD (mild, moderate or severe) at the point of care (figure 8) [120]. In the primary care setting, severity can be determined with the easily obtainable dyspnea intensity (using a visual analog scale (VAS) 0 to 10 dyspnea scale with zero being not short of breath at all and 10 the worst shortness of breath you have ever experienced), respiratory rate, heart rate and oxygen saturation level. Where available, measuring blood C-reactive protein (CRP) levels is recommended (figure 8). To determine the need for ventilatory support (usually in the emergency room or hospital setting) arterial blood gases should be measured. To move from a mild to a moderate level, three of the variables need to exceed the established thresholds.

It is hoped that prospective validation will help better define exacerbations and their severity at point of contact, and that documented validation may confirm or help modify the proposed thresholds of the variables now included [122]. Likewise, it is proposed that prospective research can help determine a more specific marker of lung injury than the more generic CRP, as has been true for acute events of other organs (e.g. troponin level in patients with acute myocardial infarction).

Management of ECOPD

Treatment setting

Depending on the episode severity, as well as that of the underlying COPD and comorbidities, an ECOPD can be managed in either the outpatient or inpatient setting. The following are indications for hospitalization: 1) severe symptoms such as sudden worsening of resting dyspnea, high respiratory rate, decreased oxygen saturation, confusion, drowsiness; 2) acute respiratory failure; 3) onset of new physical signs (e.g. cyanosis, peripheral edema); 4) failure to respond to initial medical management; 5) presence of serious comorbidities (e.g. heart failure, newly occurring arrhythmias); and, 6) insufficient home support [1].

In the emergency department, hypoxemic patients should be provided with the appropriate concentration of supplemental oxygen and be assessed to determine if the increased work of breathing or impaired gas exchange require noninvasive ventilation. If so, healthcare providers should consider admission to an area where proper monitoring and care can be provided. In less severe cases, the patient may be managed in the emergency department or hospital ward unit.

Pharmacological treatment

Bronchodilators

Short-acting inhaled β₂-agonists (SABA), with or without short-acting anticholinergics (SAMA), are the initial bronchodilators for acute treatment of ECOPD, administered using a metered-dose inhaler (MDI), with a spacer device if necessary, or nebulization [1]. If a nebulizer is chosen, air-driven is preferable to oxygen-driven nebulization to avoid the potential risk of increasing arterial partial pressure of carbon dioxide (P_{aCO2}) [123]. The GOLD 2023 report recommends continuing treatments with long-acting bronchodilators during the exacerbation or to start these medications as soon as possible before hospital discharge [1]. Intravenous methylxanthines (theophylline or aminophylline) are not recommended due to lack of efficacy and significant side-effects [124, 125].

Glucocorticoids

Systemic glucocorticoids in COPD exacerbations improve lung function, oxygenation, risk of early relapse, and reduce treatment failures and length of hospitalization [126–128]. A dose of 40 mg prednisone-equivalent per day for 5 days is recommended [129]. Longer courses increase risk of pneumonia and mortality [130]. Therapy with oral prednisolone is equally effective to intravenous administration [131]. Nebulized budesonide may be a suitable alternative to systemic corticosteroids in some patients [127, 132]. Recent studies suggest that glucocorticoids may be less efficacious to treat COPD exacerbations in patients with lower blood eosinophil levels [133].

Antibiotics

Antibiotics should be given to patients with ECOPD who have increased sputum volume and sputum purulence and most of those requiring mechanical ventilation (invasive or noninvasive) [134]. The recommended length of antibiotic therapy is 5–7 days [135]. The choice of the antibiotic should be based on the local bacterial resistance pattern. Usually, initial empirical treatment is an aminopenicillin with clavulanic acid, macrolide, tetracycline or, in selected patients, quinolone. In patients with frequent exacerbations, severe airflow obstruction and/or exacerbations requiring mechanical ventilation, cultures from sputum or other materials from the lung should be performed, as Gram-negative bacteria (e.g. Pseudomonas spp.) or resistant pathogens that are not sensitive to the above-mentioned antibiotics may be
present. The route of administration (oral or intravenous) depends on the patient’s ability to ingest medications and the pharmacokinetics of the antibiotic.

**Adjunct therapies**

Additional therapies may be indicated to maintain appropriate fluid balance, treat the comorbidities and monitor nutritional aspects. Hospitalized patients with COPD are at an increased risk of deep vein thrombosis and pulmonary embolism and prophylactic measures for thromboembolism should be instituted [136, 137]. At all times, healthcare providers should strongly enforce the need for smoking cessation.

**Oxygen therapy**

Supplemental oxygen for hypoxemia should be titrated to a target saturation of 88–92% [138]. In severe ECOPD, blood gases should be checked frequently or as clinically indicated to monitor for carbon dioxide retention and/or worsening acidosis. Pulse oximetry is not as accurate as arterial blood gas measurement [139] and, in particular, may overestimate blood oxygen content among individuals with darker skin tones [140]. Venturi masks offer more accurate and controlled delivery of inspired oxygen than do nasal prongs [1].

High-flow nasal therapy (HFNT) delivers heated and humidified air–oxygen blends via special devices at rates up to 8 L·min$^{-1}$ in infants and up to 60 L·min$^{-1}$ in adults [141]. HFNT has been associated with decreased respiratory rate and effort, improved lung mechanics and gas exchange, prolonged time to next exacerbation and improved health-related quality of life scores in COPD patients with acute (or chronic) hypercapnia [142–144], but did not prevent intubation in hospitalized patients with ECOPD [145]. In fact, the European Respiratory Society (ERS) recommends ventilatory support before using HFNT in hypercapnic ECOPD [146].

**Ventilatory support**

Ventilatory support can be provided by either noninvasive (NIV) means, with a nasal or facial mask, or invasive means, with an oro-tracheal tube or tracheostomy ventilation. NIV is the preferred initial mode of ventilation [147, 148]. It improves gas exchange and decreases respiratory rate, work of breathing, severity of breathlessness, intubation rates, complications (e.g. ventilator associated pneumonia), length of hospital stay and mortality [147, 148]. Once patients improve and can tolerate at least 4 h of unassisted breathing, NIV can be directly discontinued without any need for a “weaning” period [149].

Patients who fail NIV should receive invasive ventilation as subsequent rescue therapy [150]. The use of invasive ventilation in COPD is influenced by the likely reversibility of the precipitating event, the patient’s wishes, and the availability of intensive care facilities [150]. When possible, advance directives or a “living will” makes these difficult decisions easier to resolve. Major hazards include the risk of ventilator-acquired pneumonia, barotrauma and volutrauma, and the risk of tracheostomy and consequential prolonged ventilation. Respiratory stimulants (e.g. caffeine, doxapram) are not recommended to treat ECOPD [1].

**Hospital discharge, early readmissions, and follow-up**

There are no standards to the timing and nature of hospital discharge but early readmissions during the first 90 days after discharge are frequent and constitute a significant healthcare problem. A systematic review has shown that comorbidities, previous exacerbations and hospitalization, and increased length of stay were significant risk factors for 30- and 90-day all-cause readmission after a hospitalized COPD exacerbation [151]. Hence, after an exacerbation it is good practice to cover education on correct use of the medications, provide support at home and a follow-up plan before discharge [152]. Early follow-up (within 1 month) should also be scheduled as it has been related to less exacerbation-related readmissions [153]. Additional follow-up at 3 months is recommended to ensure return to a stable clinical state and permit a review of the patient’s symptoms, lung function, and where possible the assessment of prognosis using multiple scoring systems such as the BODE [154]. In addition, arterial oxygen saturation and arterial blood gas assessment will determine the need for long-term oxygen therapy more accurately [155]. The effects of initiation of pulmonary rehabilitation in the first 4 weeks after hospital discharge are unclear [156, 157].

**Prognosis**

Long-term prognosis following hospitalization for COPD exacerbation is poor, with a 5-year mortality rate of about 50% [158]. Factors independently associated with poor outcome include older age, lower body mass index, comorbidities (e.g. cardiovascular disease or lung cancer), previous hospitalizations for COPD exacerbations, clinical severity of the index exacerbation and need for long-term oxygen therapy at discharge [159–161].
Comorbidities, multimorbidity and frailty

COPD almost invariably coexists with other diseases (see below) that may significantly impact the patient’s clinical condition and prognosis [162]. These comorbid conditions complicate the clinical picture because they can mimic the clinical presentation of COPD with similar complaints of dyspnea and chest tightness/pain and lead to misdiagnosis and missed opportunities for treatment. Additionally, comorbid conditions can further limit the pulmonary reserve of patients with COPD. Conversely, COPD may adversely affect the outcomes of many other disorders. For example, patients with heart failure or those undergoing coronary artery bypass grafting have greater morbidity and mortality when COPD is present compared to when it is absent. Some comorbidities arise independently of COPD, but others are causally related, either by shared risk factors or by one disease compounding the severity of the other [163].

In general, the presence of comorbidities should not alter COPD treatment and comorbidities should be treated per usual standards regardless of the presence of COPD. Attention should be directed to ensure simplicity of treatment and to minimize polypharmacy.

Cardiovascular diseases

Cardiovascular diseases are common in COPD, their prevalence ranging from 20 to 70% [164]. The types of cardiovascular comorbid conditions are diverse and span the spectrum from congestive heart failure to ischemic heart disease, arrhythmias, peripheral vascular disease and hypertension [164]. All these conditions should be treated in patients per established guidelines independent of the COPD diagnosis, including the use of selective β1-blockers when a clear cardiovascular indication is present.

Lung cancer

Lung cancer occurs frequently in patients with COPD [165]. Like the general population, annual low-dose CT scan is recommended for lung cancer screening in COPD due to smoking [78, 79]. In patients with COPD not due to smoking, there is insufficient data to establish benefit over harm from lung cancer screening.

Bronchiectasis

Bronchiectasis affects approximately 30% of patients with COPD [166]. Increased sputum production, recurrent infections, and more frequent exacerbations hallmark bronchiectasis when it accompanies COPD. A chest CT scan is recommended if bronchiectasis is suspected.

Sleep apnea

Sleep apnea occurs in approximately 14% of COPD patients [167]. This worsens their prognosis since they have more frequent episodes of oxygen desaturation and a longer sleep time with hypoxemia and hypercapnia than obstructive sleep apnea patients without COPD.

Osteoporosis

Osteoporosis in COPD is often under-diagnosed and associated with poor health status and prognosis [168]. Recurrent use of systemic corticosteroids increases the risk of osteoporosis and should be avoided if possible.

Diabetes and metabolic syndrome

Studies show that diabetes is more frequent in COPD and the latter is likely to affect prognosis [164]. The prevalence of metabolic syndrome has been estimated to be more than 30% [169]. Diabetes and metabolic syndrome should be treated according to usual guidelines. COPD should be treated as usual.

Gastroesophageal reflux

Gastroesophageal reflux (GERD) is an independent risk factor for exacerbations and is associated with worse health status [170, 171]. The mechanisms responsible for increased risk of exacerbations are not yet fully established. Proton pump inhibitors are often used for treatment of GERD. One small, single-blind study suggested that these agents decrease the risk of exacerbation [172], but their value in preventing these events remains controversial, and the most effective treatment for this condition in COPD has yet to be established [173].

Anemia

Anemia is frequent in patients with COPD [174]. These patients are generally older, have more frequent cardiometabolic comorbidities, greater dyspnea, worse quality of life and airflow obstruction, reduced exercise capacity, and an increased risk of severe exacerbations with a higher mortality.
Secondary polycythemia

Secondary polycythemia may be associated with pulmonary hypertension [175, 176], venous thromboembolism [176], and mortality. Although the prevalence of polycythemia in COPD has decreased following the introduction of long-term oxygen therapy (LTOT) [177], one study reported its presence in 8.4% of patients with severe COPD receiving LTOT [178].

Mental health

Anxiety and depression are important and under-diagnosed comorbidities in COPD [179–182]. Both are associated with poor prognosis [181, 183], younger age, female sex, smoking, lower FEV₁, cough, higher St George’s Respiratory Questionnaire (SGRQ) score, and a previous history of cardiovascular disease [179, 182, 184]. Cognitive impairment occurs in 32% of people with COPD, but neuropsychological testing suggests that up to 56% of them may suffer from it [185, 186].

Multimorbidity and frailty

An increasing number of aging patients suffer multimorbidity, defined as the presence of two or more chronic conditions. These patients have symptoms from multiple diseases making their presentation complex in the acute or chronic state. Multimorbidity results in frailty hallmarked by the presence of weakness, fatigue, exhaustion, low physical activity, and unintentional weight loss [187], a condition that has been reported to be more prevalent in patients with COPD.

COPD and COVID-19

Patients should follow basic infection control measures to help prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, including social distancing and washing hands, which are associated with reductions in the incidence of COVID-19 [188]. They should have COVID-19 vaccination in line with national guidelines. At times of high community incidence of COVID-19, patients should be advised to wear a facial covering [1] and should keep taking their oral and inhaled respiratory medications for COPD as directed, as there is no evidence that COPD medications should be changed during the COVID-19 pandemic [189].

Marked reductions in exacerbation rates and hospitalization for COPD have been reported during the initial phases of the pandemic [190], possibly because of infection control measures. Physical distancing and shielding, or sheltering-in-place, should not lead to social isolation and inactivity. Patients should stay in contact with their friends and families by telecommunication and continue to keep active. They should also ensure they have enough medication.

COPD patients are not at increased risk of infection with SARS-CoV-2, but this may reflect the effect of protective strategies [189, 191]. After accounting for potential confounding variables, COPD patients do have a higher risk of hospitalization, intensive care unit admission, and mortality [191]. COPD patients presenting with new or worsening respiratory or other symptoms that could be COVID-19 related, even if these are mild, should be tested for SARS-CoV-2.

New opportunities

COPD is a common, preventable, and treatable disease, but extensive under-diagnosis and misdiagnosis leads to patients receiving no treatment or incorrect treatment [1]. The realization that environmental factors other than tobacco smoking can contribute to COPD, that it can start early in life and affect young individuals, and that there are precursor conditions (“Pre-COPD”, “PRISm”), opens new windows of opportunity for its prevention, early diagnosis, and prompt and appropriate therapeutic intervention [72]. Importantly, several pharmacological and non-pharmacological therapies have now been shown to reduce mortality of COPD patients (figure 6) but, in order to implement them, COPD must be diagnosed. Thus, any strategy aimed at addressing and improving the huge under-diagnosis of COPD in the community should be reinforced.

Acknowledgements: The authors acknowledge the support of Katie Langefeld and Ruth Hadfield for their careful editing of this 2023 GOLD report, as well as that of the members of the GOLD Emeriti Academy, GOLD Assembly and industry stakeholders for their comments and feedback.

Conflict of interest: A. Agustí is Chair of the Board of Directors of GOLD (no payment received), and reports grants or contracts from AZ, GSK, Chiesi and Menarini, consultancy fees from AZ, GSK, Chiesi, Menarini, Zambon, MSD and Sanofi, and payment or honoraria for lectures, presentations, manuscript writing or educational events from AZ, GSK, Chiesi, Menarini and Zambon, outside the submitted work. B.R. Celli reports support for the present work.
from Chiesi Farmaceutici; grants or contracts from GlaxoSmithKline, AstraZeneca, Menarini, Sanofi Aventis and Asios, consultancy fees from GlaxoSmithKline, AstraZeneca and Sanofi Aventis, payment or honoraria for lectures, presentations, manuscript writing or educational events from GlaxoSmithKline, AstraZeneca, Menarini, Chiesi and Regeneron, support for attending meetings and/or travel from GlaxoSmithKline and Sanofi Aventis, and participation on a data safety monitoring board or advisory board for AZ Therapeutics, Sanofi Aventis and Vertex, outside the submitted work. G.J. Criner reports support for the present work from GlaxoSmithKline; grants or contracts from Alung Technologies Inc., American College of Radiology, American Lung Association, AstraZeneca, BioScale Inc., Boehringer Ingelheim, BREATHTherapeutics Inc., COPD Foundation, Coridea/ZIDAN, Corvus, Dr Karen Burns of St Michael’s Hospital, Fisher & Paykel Healthcare Ltd, Galapagos NV, GlaxoSmithKline, Kinevent, Lungpacer Medical Inc., National Heart, Lung, and Blood Institute, Nurvaira Inc., Patient-Centered Outcomes Research Institute, Pulmonary Fibrosis Foundation, PulmonX, Respironics Inc., Respivant Sciences, Spiration Inc., Steward St Elizabeth’s Medical Center of Boston Inc. and Veracyte Inc., and personal fees from Amgen, AstraZeneca, Boehringer Ingelheim, Broncus Medical, CSA Medical, ELOO Medical, Gala Therapeutics, GlaxoSmithKline, Helios Medical, Ion, Merck, Medtronic, Mereo BioPharma, NGM Biopharmaceuticals, Novartis, Olympus, PulmonX, Respironics Inc., Respivant Sciences, The Implementation Group and Verona Pharma, outside the submitted work. D. Halpin reports payment or honoraria for lectures, presentations, manuscript writing or educational events from AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Novartis, Pfizer, Sanofi and Menarini, support for attending meetings and/or travel from Menarini, and participation on a data safety monitoring board or advisory board with Chiesi, outside the submitted work. A. Anzueto reports consultancy fees from GlaxoSmithKline, AstraZeneca and Boehringer Ingelheim, and payment or honoraria for lectures, presentations, manuscript writing or educational events from Viatrix Pharma, outside the submitted work. P. Barnes reports grants or contracts from AstraZeneca and Boehringer Ingelheim, consultancy fees from AstraZeneca, Boehringer Ingelheim, Novartis, Teva and Epi-Endo, and payment or honoraria for lectures, presentations, manuscript writing or educational events from AstraZeneca, Boehringer Ingelheim, Novartis and Teva, outside the submitted work. J. Bourbeau reports grants or contracts from Canadian Institute of Health Research (CIHR), Réseau en santé respiratoire du FRQS, McGill University, McGill University Health Centre Foundation, AstraZeneca Canada Ltd, Boehringer Ingelheim Canada Ltd, GlaxoSmithKline Canada Ltd, Grifols, Novartis, Sanofi and Trudell Canada Ltd, and payment or honoraria for lectures, presentations, manuscript writing or educational events from AstraZeneca Canada Ltd, COVIS Pharma Canada Ltd, GlaxoSmithKline Canada Ltd, Pfizer Canada Ltd and Trudell Canada Ltd, outside the submitted work. M.K. Han reports grants or contracts from NIH, Novartis, Nuivara, Sunovion, Gala Therapeutics, COPD Foundation, AstraZeneca, American Lung Association, Boehringer Ingelheim and Biodexis, royalties or licences from Uptodate, Norton Publishing and Penguin Random House, consultancy fees from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Pulmonx, Teva, Verona, Merck, Mylan, Sanofi, DevPro, Aerogen, Polarian, United Therapeutics, Regeneron, Altesa BioPharma and Amgen, payment or honoraria for lectures, presentations, manuscript writing or educational events from Cipla, Chiesi, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Medscape, Integrity and NACE, participation on a data safety monitoring board or advisory board with Novartis and Medtronic, leadership or fiduciary roles with COPD Foundation, COPD Foundation Scientific Advisory Committee, ALA advisory committee, American Thoracic Society (journal editor), ALA (volunteer spokesperson), GOLD scientific committee and Emerson School Board, stock or stock options with Meissa Vaccines and Altesa BioPharma, receipt of equipment, materials, drugs, medical writing, gifts or other services from GSK, Boehringer Ingelheim, AstraZeneca and Novartis, and personal fees from Medscape and Integrity, outside the submitted work. F.J. Martinez reports grants or contracts from AstraZeneca, Chiesi, GSK and Sanofi/Regeneron, consultancy fees from AstraZeneca, Boehringer Ingelheim, Chiesi, CSL Behring, GSK, Novartis, Polarean, Pulmonx, Sanofi/Regeneron, Sunovion, Teva, Theravance/Viatrix and UpToDate, payment or honoraria for lectures, presentations, manuscript writing or educational events from Cipla and GlaxoSmithKline, outside the submitted work. J. Bourbeau reports grants or contracts from AstraZeneca, Boehringer Ingelheim, Chiesi, CSL Behring, GSK, Novartis, Pulmonx, Sanofi/Regeneron, Sunovion, Teva, Theravance/Viatrix and UpToDate, outside the submitted work. M. Montes de Oca reports grants or contracts from AstraZeneca, Boehringer Ingelheim, Chiesi, CSL Behring, GSK, Novartis, Pulmonx, Sanofi/Regeneron, Sunovion, Teva, Theravance/Viatrix and UpToDate, outside the submitted work. K. Mortimer has contributed to advisory boards for AstraZeneca and GlaxoSmithKline, outside the submitted work. A. Papi reports grants or contracts from Chiesi, AstraZeneca, GSK, Sanofi and Agenzia Italiana del Farmaco (AIFA), consultancy fees from Chiesi, AstraZeneca, GSK, Novartis, Sanofi, Avillion and Elpen Pharmaceuticals, payment or honoraria for lectures, presentations, manuscript writing or educational events from Chiesi, AstraZeneca, GSK, Menarini, Novartis, Zambon, Mundipharma, Sanofi, Edmond Pharma, IQvia, Avillion and Elpen Pharmaceuticals, and participation on a data safety monitoring board or advisory board for Chiesi, AstraZeneca, GSK, MSD, Novartis, Sanofi, IQvia, Avillion and Elpen Pharmaceuticals, outside the submitted work. I. Pavord reports speaker fees from Aerocrine AB, speaker and consultancy fees from Almirall and Novartis, speaker fees, payments for organization of educational events, consultancy fees and international scientific meeting sponsorship from AstraZeneca, GSK, Regeneron Pharmaceuticals, Inc., Sanofi and Teva, speaker fees, consultancy fees and international scientific meeting sponsorship from Boehringer Ingelheim, speaker fees, consultancy fees, research grants and international scientific meeting sponsorship from Chiesi, consultancy fees from Circassia, Dey Pharma, Genentech, Knopp Biosciences, Merck, MSD, RespiVert and Schering-Plough, and consultancy fees and international scientific meeting
sponsoring from Napp Pharmaceuticals, outside the submitted work. N. Roche reports grants or contracts from Boehringer Ingelheim, Novartis, GSK and Pfizer, consultancy fees from Boehringer Ingelheim, GSK, AstraZeneca, Sanofi, Chiesi, Pfizer, Novartis, Teva and Bayer, and payment or honoraria for lectures, presentations, manuscript writing or educational events from Boehringer Ingelheim, GSK, AstraZeneca, Sanofi, Chiesi, Pfizer, Novartis, Teva, Zambon and MSD, outside the submitted work. D.D. Sin reports payment or honoraria for lectures, presentations, manuscript writing or educational events from AstraZeneca, Boehringer Ingelheim and GSK, outside the submitted work. D. Singh reports consultancy fees from Aerogen, AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, CSL Behring, Epiendo, Genentech, GlaxoSmithKline, Glenmark, GossamerBio, Kinaset, Menarini, Novartis, Pulmatrix, Sanofi, Synairgen, Teva, Theravance and Verona, outside the submitted work. R. Stockley reports consultancy fees from CSL Behring and Mereo Biopharma, and participation on a data safety monitoring board or advisory board for Kamada and Syneos, outside the submitted work. J.A. Wedzicha reports grants or contracts from AstraZeneca, Boehringer, Chiesi, GSK, Novartis, Genentech and 37Clinical, consultancy fees from AstraZeneca, Epiendo, GSK, Gilead, Novartis, Pieris and Pulmatrix, payment or honoraria for lectures, presentations, manuscript writing or educational events from AstraZeneca, GSK, Boehringer, Recipharm and Novartis, and participation on a data safety monitoring board or advisory board for Virtus, outside the submitted work. C.F. Vogelmeier reports grants or contracts from German Ministry of Education and Science (BMBF), AstraZeneca, Boehringer Ingelheim, Chiesi, CSL Behring, GlaxoSmithKline, Grifols and Novartis, consultancy fees from Aerogen, AstraZeneca, Boehringer Ingelheim, CSL Behring, Chiesi, GlaxoSmithKline, Insmed, Menarini, Novartis and Nuvaira, and payment or honoraria for lectures, presentations, manuscript writing or educational events from Aerogen, AstraZeneca, Boehringer Ingelheim, CSL Behring, Chiesi, GlaxoSmithKline, Insmed, Menarini, Novartis, Roche and Sanofi, outside the submitted work. The remaining authors have no potential conflicts of interest to disclose.

References


3 Global Initiative for Chronic Obstructive Lung Disease. 2022 Global Strategy for Prevention, Diagnosis and Management of COPD. www.goldcopd.org


Clinical indications for noninvasive positive pressure ventilation in chronic respiratory failure due to obstructive pulmonary disease.


